- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04227483
Deflazacort vs. Prednisolone in Acute-stage ABPA
A Randomized Controlled Trial of Deflazacort vs. Prednisolone in Acute-stage Allergic Bronchopulmonary Aspergillosis
Oral glucocorticoids are currently the treatment of choice for allergic bronchopulmonary aspergillosis (ABPA). They not only suppress the immune hyperfunction but are also anti-inflammatory. Unfortunately, numerous toxicities and adverse effects have been attributed to glucocorticoids related to both the average dose and cumulative duration of use.
Deflazacort is a oxazoline steroid with demonstrated anti-inflammatory and immunosuppressant effects. The novel structural characteristic of deflazacort is associated with substantial lack of sodium-retaining activity, lower interference with carbohydrate metabolism and calcium metabolism in comparison with older glucocorticoids such as prednisolone. The investigators hypothesize that the occurrence of side-effects, primarily weight gain will be lower with deflazacort. In this study, the investigators will compare the safety and efficacy of deflazacort in the treatment of acute-stage ABPA complicating asthma.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Depending on the host immunity and the organism virulence, the respiratory diseases caused by Aspergillus are classified as saprophytic (aspergilloma), allergic (allergic aspergillus sinusitis and allergic bronchopulmonary aspergillosis) and invasive (acute invasive pulmonary aspergillosis, subacute invasive pulmonary aspergillosis and chronic pulmonary aspergillosis). Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder caused by a complex hypersensitivity response to the antigens released by the fungus Aspergillus fumigatus. The disorder clinically manifests as chronic asthma, recurrent pulmonary infiltrates, and bronchiectasis. The clinical entity was first described by Hinson et al in 1952,4 and the clinical and immunologic significance of Aspergillus fumigatus in the sputum were reported by Pepys and coworkers in 1959.5 The condition has immunologic features of immediate hypersensitivity (type I), antigen-antibody complexes (type III), and eosinophil-rich inflammatory cell responses (type IVb), based on the revised Gell and Coombs classification of immunologic hypersensitivity. Occasionally, patients can develop a syndrome similar to ABPA but is caused by fungi other than A.fumigatus and is termed as allergic bronchopulmonary mycosis. The condition remains underdiagnosed in many countries with reports of mean diagnostic latency of ten years between the occurrence of symptoms and the diagnosis.9 In the past two decades, there has been an increase in the number of cases of ABPA due to the heightened physician awareness and the widespread availability of serologic assays.
The diagnostic criteria for ABPA have been recently revised and includes the following: (a) history of asthma; (b) pulmonary opacities consistent with ABPA; (c) raised A. fumigatus specific IgE >0.35 kUA/L; (d) peripheral blood eosinophil count >500 cells/µL; (e) raised A. fumigatus specific IgG levels >27 mgA/L; (f) total IgE levels >1000 IU/mL. The prevalence of ABPA in bronchial asthma is fairly high and a recent meta-analysis suggested the prevalence of ABPA in asthma clinics to be as high as 13 percent. The global burden of ABPA has been estimated to be about 5 million cases. The disorder is highly prevalent in India, and there are an estimated 1.4 million cases in India alone.
Oral glucocorticoids are currently the treatment of choice for ABPA. They not only suppress the immune hyperfunction but are also anti-inflammatory. Different regimens of glucocorticoids have been used in literature. In a recent study, it was found that lower doses of glucocorticoids are as effective as higher doses in the therapy of acute-stage ABPA. Unfortunately, numerous toxicities and adverse effects have been attributed to glucocorticoids related to both the average dose and cumulative duration of use. The serious toxicities include hyperglycemia, increased loss of bone mineral density, reports of avascular necrosis, myopathy, excess cardiovascular events or heart disease, increased blood pressure, serious cutaneous side effects, upper gastrointestinal ulcers or bleeding, pancreatitis, increased risk of infection, psychosis, or mood disturbances. In one study, the average daily dose of glucocorticoid was the strongest predictor of a serious side-effect potentially attributable to glucocorticoid (prednisone) therapy (odds ratio of 4.5 and 32.3 for 5-10 mg and 10-15 mg prednisone, respectively). In another study, the risk of adverse events with low-dose glucocorticoids (prednisone 5-10 mg/day) was small. However, even with low-dose steroid there is an increase in body weight including the appearance of cushingoid facies.
Deflazacort is a heterocyclic glucocorticoid prodrug belonging to the class of oxazoline steroids, with demonstrated anti-inflammatory and immunosuppressant effects. The novel structural characteristic of deflazacort is associated with substantial lack of sodium-retaining activity, lower interference with carbohydrate metabolism and calcium metabolism (with lower propensity for bone loss) in comparison with older glucocorticoids such as prednisolone. The investigators hypothesize that the occurrence of side-effects, primarily weight gain will be lower with deflazacort.
In this study, the investigators will compare the safety and efficacy of deflazacort in the treatment of acute-stage ABPA complicating asthma.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Ritesh Agarwal, MD, DM
- Phone Number: 00911722756825
- Email: agarwal.ritesh@outlook.in
Study Contact Backup
- Name: Valliappan Muthu, MD, DM
- Phone Number: 00911722756820
- Email: valliappa@gmail.com
Study Locations
-
-
-
Chandigarh, India, 160012
- Chest Clinic, Dept. of Pulmonary Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients aged 18-65 years will be included in the study if they meet the modified ISHAM-ABPA working group criteria defined by the presence of all the following three criteria:
- Asthma
- A.fumigatus-specific IgE levels > 0.35 kUA/L
- Elevated serum total IgE levels > 1000 IU/mL; and two of the following criteria:
- Presence of elevated A fumigatus-specific IgG >27 mgA/L;
- Radiographic pulmonary opacities consistent with ABPA
- Peripheral blood eosinophil count >500/µL.
Exclusion Criteria:
- Taken any prior treatment for ABPA (systemic glucocorticoids, antifungal drugs)
- Failure to give informed consent
- Enrollment in another trial of ABPA
- Pregnancy
- Any of the following comorbidity: diabetes mellitus, glaucoma, chronic liver disease and chronic kidney disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Prednisolone
Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks.
Then taper by 5 mg every 2 weeks and discontinue.
All doses will be rounded off to the nearest 5 mg (maximum duration of therapy, 4 months)
|
Prednisolone for 4 months
|
Experimental: Deflazacort
Deflazacort 0.75 mg/kg/day for 4 weeks; 0.375 mg/kg/day for 4 weeks; 0.1875 mg/kg/day for 4 weeks.
Then taper by 6 mg every 2 weeks and discontinue.
All doses will be rounded off to the nearest 6 mg (maximum duration of therapy, 4 months)
|
Deflazacort for 4 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weight gain
Time Frame: 2 months
|
Weight at 2 months minus the baseline weight
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decline in serum total IgE levels
Time Frame: 2 months
|
((Baseline IgE minus serum total IgE at 2 months)/Baseline IgE) * 100
|
2 months
|
Decline in serum total IgE levels
Time Frame: 4 months
|
((Baseline IgE minus serum total IgE at 4 months)/Baseline IgE) * 100
|
4 months
|
Response rates
Time Frame: 2 months
|
Decline in serum total IgE levels by ≥25% AND clinical improvement or partial/total clearance (>50%) of chest radiographic lesions after two months
|
2 months
|
Response rates
Time Frame: 4 months
|
Decline in serum total IgE levels compared to the value at 2 months AND clinical improvement or partial/total clearance (>50%) of chest radiographic lesions after two months
|
4 months
|
Exacerbation rates
Time Frame: 1 year
|
50% increase in the 'new' baseline serum total IgE levels along with clinical or radiological deterioration
|
1 year
|
Exacerbation rates
Time Frame: 2 year
|
50% increase in the 'new' baseline serum total IgE levels along with clinical or radiological deterioration
|
2 year
|
Adverse events
Time Frame: 2 months
|
Cushingoid habitus, acne, striae, hypertension, hyperglycemia
|
2 months
|
Adverse events
Time Frame: 4 months
|
Cushingoid habitus, acne, striae, hypertension, hyperglycemia
|
4 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bacterial Infections and Mycoses
- Respiratory Hypersensitivity
- Hypersensitivity
- Mycoses
- Lung Diseases, Fungal
- Aspergillosis
- Pulmonary Aspergillosis
- Aspergillosis, Allergic Bronchopulmonary
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Prednisolone
- Deflazacort
Other Study ID Numbers
- RA/2020/001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Bronchopulmonary Aspergillosis
-
Postgraduate Institute of Medical Education and...CompletedAllergic Bronchopulmonary AspergillosesIndia
-
University Hospital, MontpellierCompletedSevere Asthma | Allergic Bronchopulmonary Aspergillosis (ABPA)France
-
University Hospital, BordeauxCompletedAllergic Bronchopulmonary AspergillosesFrance
-
Postgraduate Institute of Medical Education and...RecruitingAllergic Bronchopulmonary Aspergillosis | Chronic Pulmonary AspergillosisIndia
-
Shanghai Zhongshan HospitalNot yet recruitingAllergic Bronchopulmonary Aspergillosis
-
Shanghai Pulmonary Hospital, Shanghai, ChinaRecruiting
-
Postgraduate Institute of Medical Education and...Cipla Ltd.CompletedAllergic Bronchopulmonary AspergillosisIndia
-
Regeneron PharmaceuticalsSanofiCompletedAllergic Bronchopulmonary AspergillosisUnited States, Hungary, Bulgaria, France, Germany, Japan, Netherlands, Poland, Romania, United Kingdom
-
Postgraduate Institute of Medical Education and...CompletedAllergic Bronchopulmonary AspergillosisIndia
-
Zambon SpACompletedAllergic Bronchopulmonary AspergillosisUnited Kingdom
Clinical Trials on Prednisolone
-
Children's Hospital of PhiladelphiaCompleted
-
Assiut UniversityCompleted
-
Sparrow PharmaceuticalsRecruitingPolymyalgia RheumaticaGermany
-
IsalaCompletedChronic Obstructive Pulmonary DiseaseNetherlands
-
Hamamatsu UniversityCompletedChronic Disease | Eosinophilic PneumoniaJapan
-
Postgraduate Institute of Medical Education and...Completed
-
Postgraduate Institute of Medical Education and...CompletedPost COVID-19 Diffuse Lung DiseaseIndia
-
Nanjing University School of MedicineCompleted
-
Cambridge University Hospitals NHS Foundation TrustUniversity Medical Center Groningen; Imperial College London; University Hospitals... and other collaboratorsTerminatedWegener's Granulomatosis | Microscopic PolyangiitisUnited Kingdom
-
Institute of Child HealthUnknown